Press Releases

Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library. These advances were made possible by NVIDIA DGX Cloud supercomputing and the recent acquisition of Cyclica’s

Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein interactions for approximately 36 billion compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library Added, accelerated or tightened guidance for clinical study

SALT LAKE CITY , Aug. 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: KeyBanc Technology Leadership Forum  – August 6-8, 2023

Valence Labs is Recursion’s new machine learning research center that aims to promote open science and academic research. $1 million will be committed to advancing the next generation of academic machine learning research through scholarships and fellowships.

Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster SALT LAKE CITY , TORONTO and MONTRÉAL , July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize

TORONTO , June 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today celebrated the opening of its 28,000 square foot Toronto site, which will serve as the headquarters for Recursion Canada.

Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5.

SALT LAKE CITY , June 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Goldman Sachs 44th Annual Global Healthcare Conference – June

Altitude’s new facility will be housed within Recursion’s expanded headquarters and will promote increased collaboration in Downtown Salt Lake City’s rapidly growing biotech innovation ecosystem. SALT LAKE CITY , May 25, 2023 (GLOBE NEWSWIRE) -- Altitude Lab announced today that its incubator

SALT LAKE CITY , May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed David Mauro , M.D., Ph.D, as its Chief Medical Officer. Dr.